Anti-KCNQ2

0.5mg/ml if reconstituted with 0.2ml sterile DI water. KCNQ2, also called kv7.2, is a potassium channel protein coded for by the gene KCNQ2. It is mapped to 20q13.33. The KCNQ2 gene encodes a voltage-gated potassium channel that is expressed in the brain. Expression of human KCNQ2 in Xenopus laevis oocytes led to potassium-selective currents that activated slowly with depolarization. Defects in this gene are a cause of benign familial neonatal convulsions type 1 (BFNC), also known as epilepsy, benign neonatal type 1(EBN1). At least five transcript variants encoding five different isoforms have been found for this gene. Protein function: Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. Therefore, it is important in the regulation of neuronal excitability. KCNQ2/KCNQ3 current is blocked by linopirdine and XE991, and activated by the anticonvulsant retigabine (PubMed:9836639, PubMed:11572947, PubMed:14534157, PubMed:12742592, PubMed:17872363). As the native M-channel, the potassium channel composed of KCNQ2 and KCNQ3 is also suppressed by activation of the muscarinic acetylcholine receptor CHRM1 (PubMed:10684873). [The UniProt Consortium]